Research graph
References from Prior immune checkpoint inhibitor exposure, treatment interval, and severe hepatotoxicity with sotorasib in KRAS G12C-mutant non-small-cell lung cancer: a systematic review and meta-analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
Advances in the treatment of KRAS(G12C) mutant non-small cell lung cancer
2025 · External reference
10.1016/s0140-6736(23)00221-0
10.1016/s0140-6736(23)00221-0 · External reference
10.1016/s0140-6736(25)00866-9
10.1016/s0140-6736(25)00866-9 · External reference
Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report
2021 · External reference
Immunological Drug-Drug Interactions Affect the Efficacy and Safety of Immune Checkpoint Inhibitor Therapies
10.1021/acs.chemrestox.4c00067 · 2024 · External reference
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer
10.1016/j.jtho.2018.09.001 · 2019 · External reference
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
2023 · External reference
10.1016/j.jtho.2023.05.013
10.1016/j.jtho.2023.05.013 · External reference
Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis
10.1016/j.ebiom.2024.105074 · 2024 · External reference
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer
2023 · External reference
Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report
2023 · External reference
EP.12C.03 Toxicities associated with immune checkpoint inhibitors followed by KRAS G12C inhibitors in patients with metastatic NSCLC
10.1016/j.jtho.2024.09.1223 · 2024 · External reference
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer
10.1093/oncolo/oyae356 · 2025 · External reference
Impact of immunotherapy on sotorasib toxicity in NSCLC: A real-world matched analysis
2026 · External reference
10.1136/bmj.n71
10.1136/bmj.n71 · External reference
10.1136/bmj.l6890
10.1136/bmj.l6890 · External reference
10.1016/j.envint.2024.108602
10.1016/j.envint.2024.108602 · External reference
10.1136/bmj.39489.470347.ad
10.1136/bmj.39489.470347.ad · External reference
10.1002/sim.1761
10.1002/sim.1761 · External reference
10.1002/sim.2528
10.1002/sim.2528 · External reference
10.1002/sim.4040
10.1002/sim.4040 · External reference
10.1093/biomet/58.1.129
10.1093/biomet/58.1.129 · External reference
Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study
10.1016/j.ejca.2025.115301 · 2025 · External reference
Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C-Mutated NSCLC
10.1016/j.jtocrr.2024.100670 · 2024 · External reference
Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database
10.1007/s00262-024-03858-4 · 2024 · External reference
Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRAS(G12C)-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review
2024 · External reference
Unresolved reference
External reference
